Eban II: Intervention for HIV Sero-Discordant Couples

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans.

The Specific Aims are as follows:

1. To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information.
2. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.)
3. To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of a Risk Reduction Program in Preventing the Transmission of HIV and Sexually Transmitted Diseases in African-American Couples

NCT00644163

HIV Infections Sexually Transmitted Disease

COMPLETED NA

Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)

NCT04504981

HIV Drug Use

COMPLETED NA

Couples HIV Counseling and Testing for Male Couples in the United States

NCT01861210

HIV

COMPLETED NA

Dyadic-Based Diagnosis, Care, and Prevention for HIV Discordant Couples in Tanzania

NCT03098693

HIV

COMPLETED

Managerial Database II

NCT01009827

HIV

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The HIV/AIDS epidemic continues to disproportionately affect African Americans. The rate of HIV among African American men is six times the rate for White men and the rate among African American women is almost 15 times the rate for White women. An estimated 56,300 new HIV cases was reported in 2006, of which 49% were among African Americans and 80% were from heterosexual transmission. Sexually transmitted infections (STIs) also disproportionately affect African Americans, further increasing the risk for HIV transmission. Despite the fact that HIV and STIs are primarily transmitted in the context of relationships, few interventions address HIV risk in couples. Furthermore, few evidence-based HIV prevention interventions have been implemented in community-based organizations (CBOs). Thus, there is a substantial need to strengthen the availability and use of relationship oriented prevention interventions in community-based treatment settings.

This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles Counties) that have a high prevalence of HIV infection and risk conditions among African Americans.

This study builds upon the multi-site, NIMH-funded "Eban" (a Yoruba term for "fence") trial, which tested this culturally congruent intervention versus a control condition among 535 heterosexual HIV serodiscordant couples in four cities. Couples in the intervention had significantly reduced incidents of unprotected sex and an increased proportion of condom use compared to couples in the control condition. Statistical projections from that study suggest that if Eban participants had not received the intervention, six female and four males would have been infected in one year, and 25 females and 15 males would have become HIV-infected in the next 5 years. Based on these successful outcomes in a controlled trial, it is now appropriate to test the effectiveness of the intervention as delivered in community-based setting. Thus, we propose to conduct a study of implementation - a study of methods to promote the uptake of Eban into community-based organizations (CBOs).

The Specific Aims are as follows:

1. To evaluate implementation of Eban for HIV serodiscordant African American couples in 10 CBOs in California. To do this, we will document the implementation process and identify barriers and facilitators to Eban's adoption and use by the CBOs. We will interview 200 staff at CBOs to obtain this information.
2. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples, specifically incidents of protected sex, proportion of condom use, and incident sexually transmitted infections. Eban will be assessed using a randomized delayed enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and offered to couples and evaluated for effectiveness - that is, how well it works in the real world.)
3. To determine the cost-effectiveness of implementation of Eban, based on implementation costs and potential cost savings.

So please note, there are essentially two levels to this study -- first to see how well community agencies can implement or take up and execute the intervention (thus, the interviews with staff) - and the second, to see how effective Eban is in real world setting. We know it was highly effective in a controlled study but now we need to test how well it works in the "real" world(thus, the testing of the intervention with 180 couples). While doing this, we will also be examining the cost-effectiveness of the intervention in the "real" world setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexually Transmitted Diseases Disease Transmission, Infectious Safe Sex HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Risk Reduction

The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:

* Provide HIV and STI test results
* First Interview
* Attend 8 sessions - 1 session per week
* Second interview occurs immediately following the 8th session with HIV and STI tests
* Third interview occurs 3 months after the 8th session with HIV and STI tests

Group Type EXPERIMENTAL

Risk Reduction

Intervention Type BEHAVIORAL

Waitlist

The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.

* Provide HIV and STI test results
* First Interview
* No sessions for 8 weeks
* Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled
* Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.
* Attend 8 sessions - 1 session per week
* Fourth interview occurs immediately after the 8th session with HIV and STI tests
* Fifth interview occurs 3 months after the 8th session with HIV and STI tests

Group Type ACTIVE_COMPARATOR

Risk Reduction

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Risk Reduction

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be in a relationship with study partner for at least 3 months
* Both partners must be 18 years or older
* At least one partner must identify as African American/Black
* One partner must be HIV positive and one partner must be HIV negative
* Must be a heterosexual couple (one biological female and one biological man)
* Not currently expecting a child and not planning on having children within the year.

Exclusion Criteria

* Less than 18 years old
* No partner
* Couple is not heterosexual
* Insufficient relationship length/commitment
* No reported incidents of unprotected intercourse in the past 90 days
* Neither partner is African American/Black
* One/both partners unaware of others HIV status
* Couple is not serodiscordant
* One/both partners reported partner violence
* HIV diagnosis received recently (less than 3 months)
* One/both partners participated in a HIV Risk Reduction study within the past 12 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gail Wyatt

Professor, Dept. of Psychiatry & Biobehavioral Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gail E Wyatt, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

John Williams, MD

Role: STUDY_DIRECTOR

University of California, Los Angeles

Brian Mittman, PhD

Role: STUDY_DIRECTOR

VA Office of Research and Development

Alison Hamilton, PhD

Role: STUDY_DIRECTOR

University of California, Los Angeles

Hector Myers, PhD

Role: STUDY_DIRECTOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.